undamentalytics Newsletter
Sign in

Alumis Inc. revenue

Alumis Inc.'s revenue was $24.1m in fiscal 2025. Over the last twelve months it was $7.4m.

Revenue history

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2025Dec 2025LTMJun 2026
Revenue247

Revenue as reported in the company's 10-K and 10-Q filings (for banks, net interest income plus non-interest income). Growth is left blank when the earlier figure was zero or negative.

Where the revenue comes from

Fiscal year to December 31, 2025
Products and services
Line of business Revenue Share YoY
Licenses $17.4M 72.3% —
Collaboration Revenue $6.7M 27.7% —

From Alumis Inc.'s 10-K filed March 19, 2026, as tagged in the filing. View filing. Indented rows are part of the line above; their share is of that line. In the bars, the faint bar behind is the year before.

Revenue against peers

Biotechnology: the closest covered companies by revenue. Last twelve months.

CompanyRevenueGrowth3-year growth a year
Alumis Inc. $7.4m — —
Evaxion A/s $7.5m 125.1% —
Roivant Sciences Ltd. $7.5m -67.6% -46.4%
Adagene Inc. $7.7m 7332.8% —
Tscan Therapeutics, Inc. $7.1m 2.2% -24.3%
Coya Therapeutics, Inc. $8.0m 1793.8% —

Compare with peers

Head to head: ALMS vs EVAXALMS vs ROIVADAG vs ALMS

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Alumis Inc.'s SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Alumis Inc.